RemeGen
荣昌生物

RemeGen
2026 Q3 Results

October, 2026

Disclaimer

The documents, opinions and materials presented in this presentation (the “Document”) have been prepared by RemeGen Co., Ltd. (the “Company”) for use in presentations by the Company and does not constitute a recommendation regarding the securities of the Company. You fully understand that the Document is being made available on a confidential basis and subject to the following provisions. The contents of this Document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this Document in certain jurisdictions may be restricted by law, and the recipients into whose possession this Document comes should inform themselves about, and observe such restrictions. By accessing this Document, you are agreeing (i) that you have read and agree to comply with the contents of this notice and disclaimer and (ii) to maintain absolute confidentiality regarding the information disclosed in this Document.

This Document has not been independently verified and is not intended to form the basis of any investment decision. It does not constitute an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities in any jurisdiction in which the making of such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise be in compliance with the laws and regulations of such jurisdiction, and nothing contained herein shall form the basis of any investment decision, contract or commitment whatsoever. This Document contains no information or material which may result in it being deemed (1) to be an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “Securities and Futures Ordinance”) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong, and is subject to material change without notice.

The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or under the laws of any state of the United States. This Document does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States and is not for distribution and may not be distributed, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). The securities of the Company will not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the U.S. Securities Act. There will be no public offer of the Company’s securities in the United States.

This Document and the information contained herein as well as information presented orally or otherwise are strictly confidential and must be treated as such. Neither the information contained in this Document nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, PRC, Hong Kong or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other jurisdiction's securities laws. Upon request, the recipient will promptly return this Document and any other written information made available in the presentation, without retaining any copies.

This Document does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the Group. No representation, warranty or undertaking, express or implied, is given and, so far as is permitted by law, no responsibility or liability is accepted by any person (for the avoidance of doubt, including but not limited to, the Company and its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing), with respect to the accuracy, reliability, correctness, fairness or completeness of this Document or its contents. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects", “intends”, “plans to” and "anticipates" and words of similar import. These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about the Company’s operations and factors beyond the Company’s control and are subject to significant risks and uncertainties, and, accordingly, actual results may differ materially from these forward-looking statements. In particular, but without limitation, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any assumptions, projections, targets, estimates, forecasts or any forward-looking statements contained in this Document. Each of the Company and its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing assumes no obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that occur subsequent to such dates. None of the Company and any of its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of, or reliance upon, the information contained herein by you or any person to whom the information herein is disclosed.

In furnishing this Document, the Company and its affiliates undertake no obligation to provide any additional information or to update this Document or any additional information or to correct any inaccuracies which may become apparent.

Key Financial Summary

Strong Revenue Growth



Costs Under Control



Improving Commercialization Efficiency



Sustainable profitability in Sight



- *The balance of cash and cash equivalents was 3.89 billion RMB on 9/30/2026*

Pipeline at a Glance



Pipeline at a Glance



A Solid Platform Drives for Innovation and Profitability

2 Commercialized Drugs

- ***Telitacicept*** *- FIC BAFF-April fusion protein drug globally*
- ***Disitamab Vedotin (DV)*** *- First domestic HER-2 ADC launched in China*

A Pipeline with Width and Depth

- ***5+*** *proprietary new molecules in clinical stage*
- ***30+*** *clinical trials ongoing*
- ***20+*** *pre-IND stage projects*

4 Drugs in *USD12B+* Partnership Package

- ***Telitacicept*** *with* ***Vor Bio***
- ***Disitamab Vedotin*** *with* ***Pfizer***
- ***RC148*** *with* ***AbbVie***
- ***RC28*** *with* ***Santen (China)***

Strong Financial Position

- ***RMB3.8B+*** *in net cash*
- ***RMB2.1B+*** *of domestic drug sales in 2026Q1-Q3 with continued strong growth and improving margin*
- *Base business ontrack to profitability*

3300+ Employees

- ***1000+*** *R&D*
- ***1400+*** *commercialization*
- ***500+*** *manufacturing*

State-of-the-art infrastructure

- *Self owned R&D center and manufacture facility*
- ***70k+*** *Liters of biologic manufacturing facility*
- ***90k+*** *Liters of biologic manufacturing facility under construction*

A Fully Integrated Biopharma with Stellar Track Record

Company Milestone and Collaborations

- IPO
- Product launch
- Partnership

2008 — RemeGen 荣昌生物 Inception

2020-11 — HKEX 香港交易所 Listed on Hong Kong Stock Exchange

2021-03 — Telitacicept (RC18) launch

2021-06 — Disitamab Vedotin (RC48) launch

2021-08 — Pfizer / Seagen RC48 out-license to Seagen

2022-03 — SSE Shanghai Stock Exchange Listed on Shanghai Stock Exchange

2025-06 — VOR RC18 out-license to Vor Bio

2025-08 — Santen RC28 out-license to Santen

2026-01 — abbvie RC148 out-license to AbbVie

Stellar Business Development Achievements

Telitacicept （RC18）· BAFF/APRIL fusion protein

VOR BIO · JUN 2025 · TOTAL UP TO $4.23B

UPFRONT :

$45M cash + $80M warrants

MILESTONES:

up to **$4.1B** (development & commercial)

TIERED ROYALTIES ON NET SALES

Territory: worldwide ex-Greater China

RC148 · PD-1/VEGF bispecific antibody

ABBVIE · JAN 2026 · TOTAL UP TO $5.6B

UPFRONT:

$650M

MILESTONES:

up to **$4.95B** (development & commercial)

TIERED ROYALTIES ON NET SALES

Territory: worldwide ex-Greater China

Disitamab Vedotin（RC48）· HER2 ADC

PFIZER · AUG 2021 · TOTAL UP TO $2.6B

UPFRONT:

$200M

MILESTONES:

up to **$2.4B** (development & commercial)

TIERED ROYALTIES ON NET SALES

Territory: worldwide ex-Asia, plus Japan & Singapore

RC28-E · VEGF/FGF fusion protein

SANTEN (CHINA) · AUG 2025 · TOTAL OVER RMB 1.3B

UPFRONT:

RMB 250M

MILESTONES:

up to **RMB 520M** dev/reg + **RMB 525M** sales-based

TIERED ROYALTIES ON NET SALES

Territory: in Greater China and select Asian countries

Telitacicept - Maximizing Commercial Potential

5

Approved Indications for Marketing

4

Indications in Phase 3 Trials

5+

Indications in Planning/Initiating

LAUNCHED	*Pivotal/Phase 3*	*New Indications*
Systemic Lupus Erythematosus	Myasthenia Gravis	Lupus Nephritis
Myasthenia Gravis	Sjogren's Disease	Membranous Nephritis
Sjogren's Disease	Ocular Myasthenia Gravis	Pediatric IgAN
IgAN	CTD-ILD	Pediatric Systemic Lupus Erythematosus
Rheumatoid Arthritis	*Note: Collaboration with Vor Bio*	Autoimmune Hepatitis

Telitacicept – Phase III Data for Generalized Myasthenia Gravis (gMG)

Significant Change in MG-ADL (difference: -4.83) and QMG Scores (difference: -6.39) from Baseline for Telitacicept compared with Placebo at Week 24.

A **Mean Change in MG-ADL Score over 24 weeks**



B **Mean Change in QMG Score over 24 weeks**



C **Proportion of patients with a ≥3 point reduction in MG-ADL score from baseline over 24 weeks**



D **Proportion of patients with a ≥5 point reduction in QMG score from baseline over 24 weeks**



Selected for Oral Presentation at AAN 2025 and AANEM 2025 , Telitacicept showed best-in-class efficacy in Ph3 trial for gMG.

Phase 3 Clinical Trial in China
Enrolled 114 patients

- Telitacicept 240mg: 57 patients
- Placebo: 57 patients

Results of the Phase 3 Study-48 weeks

Efficacy Results of the 24-week open-label extension (OLE) period: At Week 48, in patients who continued on telitacicept vs. those who switched from placebo, change from baseline in MG-ADLand QMG was -7.5 vs.-6.3 and -9.8 vs.-9.3, respectively.

Telitacicept – Phase III Data for Sjögren's Disease (SjD)

Selected as Late-Breaking Poster at ACR 2025, Telitacicept demonstrated clinically meaningful efficacy in Ph3 trial for SjD.

Phase 3 Clinical Trial in China
Enrolled 381 patients

- Telitacicept 160mg: 127 patients
- Telitacicept 80mg: 127 patients
- Placebo: 127 patients

The primary efficacy endpoint is the change from baseline in ESSDAI score at Week 24.

Statistically significant decrease in ESSDAI score from baseline at Week 24 was observed in Telitacicept 160 mg arm (LS Mean change: -4.4 vs -0.6, p<0.0001) and in Telitacicept 80 mg arm (LS Mean change: -3.0 vs -0.6, p<0.0001) as compared with placebo.

A Change from baseline in ESSDAI score over 48 weeks



B Proportion of patients with a ≥ 3-point reduction in ESSDAI score



C Change from baseline in ESSPRI score over 48 weeks



D Proportion of patients with a ≥1 point or 15% reduction in ESSPRI score



Telitacicept – Phase III Data for IgA Nephropathy (IgAN)

Selected as Oral Presentation at ASN 2026, announced the final two-year results of the TELIGAN study for IgA nephropathy.

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Phase 3 Clinical Trial in China (TELIGAN)
Enrolled 318 patients

- Telitacicept 240mg: 159 patients
- Placebo: 159 patients

Primary endpoint: The estimated annualized slope of glomerular filtration rate (eGFR) in the tixocortin group over 104 weeks was -0.6 mL/min/1.73m²/year, while in the placebo group it was -5.7 mL/min/1.73m²/year. The difference between the two groups was 5.1 mL/min/1.73m²/year.

Annualized Total eGFR Slope Estimated over 104 Weeks





Change in eGFR over 24 months（Absolute Mean Value of eGFR ）



Disitamab Vedotin – Solidifying Competitive Position

5

Approved Indications for Marketing

4

Indications in Phase 3 Trials

2+

Indications in Planning/Initiation

LAUNCHED	*Pivotal/Phase 3*	*New Indications*
2L+ Gastric Cancer	1L Urothelial Cancer	NMIBC
2L+ Urothelial Cancer	2L Urothelial Cancer	MIBC Perioperative Period
2L+ HER2-Positive Breast Cancer with Liver Metastasis	1L HER2-Medium-to-Low Expressing Gastric Cancer	
2L+ HER2-Low Expressing Breast Cancer with Liver Metastasis	1L HER2-High Expressing Gastric Cancer	
1L Urothelial Cancer		

Note: Collaboration with Pfizer

Disitamab Vedotin – Phase III Data in 1st Line Urothelial Cancer

RemeGen 荣昌生物

Data presented at ESMO 2025 and simultaneously published in NEJM

BERLIN 2025 ESMO congress

Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la/mUC) with HER2-expression

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer

Key Inclusion criteria

- No prior systemic treatment for unresectable locally advanced or metastatic UC
- Central lab-confirmed HER2 IHC 1+, 2+, or 3+
- Measurable disease per RECIST v1.1
- Eligible for ciscplatin or carboplatin
- ECOG PS 0 or 1

R 1 : 1

N=243 **Disitamab vedotin + Toripalimab** — no set maximum cycles

N=241 **Gemcitabine + Cisplatin/Carboplatin** — a maximum of 6 cycles



	N	Events	Median PFS (95% CI), mo	Stratified HR (95% CI)	2-sided P
DV+T	243	126	13.1 (11.1-16.7)	0.36 (0.28-0.46)	<0.0001
Chemo	241	149	6.5 (5.7-7.4)		



	N	Events	Median OS (95% CI), mo	Stratified HR (95% CI)	2-sided P
DV+T	243	81	31.5 (21.7-NE)	0.54 (0.41-0.73)	<0.0001
Chemo	241	117	16.9 (14.6-21.7)		

Median follow-up: 18.2 months



2025 ESMO

Disitamab Vedotin – Phase II Data in 1st Line Gastric Cancer

Data presented at ASCO 2025

RC48 combo demonstrated promising efficacy in 1L GC HER2 expressing patients

2025 ASCO ANNUAL MEETING

Abstract number: LBA4012

Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer

HER2-positive GC







HER2-low GC







Disitamab Vedotin – Two Phase III Trials in 1st Line Gastric Cancer

RC48-C039:

1L Ph3 study in HER2 low GC



Primary endpoint
PFS (per IRC)

Key secondary endpoint
OS

RC48-C040:

1L Ph3 study in HER2 positive GC



Primary endpoint
PFS (per IRC)

Key secondary endpoint
OS

RC148 – Rapid Progress in Clinical Trials

Design of RC148

(tetravalent PD-1 xVEGF BsAb)



5+

Trials in Ph2 or Ph3 launched

5+

Trials in Planning/Initiation

Clinical progress

China

- ***Ph3 for 1L sqNSCLC*** *in combo with chemo under patient enrollment*
- ***Ph2/3 for 1L CRC*** *in combo with chemo under patient enrollment*
- ***Ph3 for 1L nsqNSCLC*** *in combo with chemo in preparation*
- *Various other trials under planning*

Global

- ***Ph3 for 1L sqNSCLC*** *in combo with chemo launched*
- *Various pivotal and Ph2 trials in preparation*

Note:collaboration with AbbVie

RC148 – Phase II Data in 1L NSCLC (2026 WCLC)

Squamous NSCLC | RC148 (10 mg/kg) + carboplatin / paclitaxel

RC148 + chemotherapy demonstrated a confirmed ORR of **76.7%** and a median PFS of **11.8 months** in first-line squamous NSCLC.





76.7%
Confirmed ORR

11.8 mo
Median PFS

NR
Median OS

Non-squamous NSCLC | RC148 (10 mg/kg) + carboplatin / pemetrexed

RC148 + chemotherapy demonstrated a confirmed ORR of **72.4%** and a median PFS of **11.1 months** in first-line non-squamous NSCLC.





72.4%
Confirmed ORR

11.1 mo
Median PFS

NR
Median OS

KEY TAKEAWAY RC148 plus chemotherapy showed robust and durable anti-tumor activity in both squamous and non-squamous 1L NSCLC; OS data remain immature (median OS not reached in either cohort).

RC278 & RC288



RC278 (Ph Ib)

Target:
CDCP1

Antibody:
A humanized mAb

Linker-Payload:
A Top1i based payload with a cleavable linker

Conjugation:
Site-specific, DAR=8

Potential indication:
CRC, Lung, Breast, Prostate, Pancreas

Development:
Ph1b: indication expansion in various solid tumors

RC288 (Ph I)

Target:
Tumor associated antigens PSMA and B7H3

Bispecific antibody:
via humanized mAb and VHH nanobody

Linker-Payload :
A Top1i based payload with a bivalent cleavable linker

Conjugation :
Site-specific, DAR=8

Key indication :
Prostate

Development :
Ph1 enrolling



Cutting-edge Technology Platforms



Target Discovery

Identify novel targets and bispecific pairs by AI-driven multi-omics deep biology network analysis



Antibody Discovery

Generate monoclonal antibody and nanobody lead molecules by hybridoma and display platforms

Protein Engineering

Deliver desired preclinical candidates (PCCs) and novel platforms via AI-guided and structure-based designs



ADC Technology

Develop novel payload, drug linker, site-specific conjugation methods to deliver ADC PCCs and next generation ADC platforms

Emerging Discovery Pipeline Highlights

RemeGen 荣昌生物

Oncology



BsADC
IND Enabling



TsADC
PCC Enabling



Dual payload ADC
PCC Enabling

Trispecific TCE
PCC Enabling

Autoimmune



Fusion Protein
IND Enabling



BsAb
PCC Enabling

TCE
PCC Enabling

MCE
PCC POC

Commercialization – Telitacicept 泰爱®

Telitacicept Revenue



Hospitals listed



Physicians covered



- First-in-class BAFF/APRIL dual-targeting drug
- Approved for SLE, IgAN, SjD, MG and RA in China

- ~900+ member rheumatology focused sales team
- Listed in ~1,200 hospital procurement list
- Covered 32,000+ targeted doctors

- New indications (OMG, CTD-ILD， cIgAN and etc) to provide sustained growth driver in the coming years
- Aim to become a leading therapy in B-cell-mediated autoimmune diseases

Commercialization – Disitamab Vedotin 爱地希®

Disitamab-Vedotin Revenue



Hospitals listed



Physicians covered



- The first domestic ADC drug approved in China
- Approved in 1L(+) UC, GC and BC patients

- ~500+ member oncology focused sales team
- Listed in ~1,090 hospital procurement list
- Covered 27,000+ targeted doctors

- Solidifying a leading position in HER-2 expressing urothelial cancer patients
- Multiple ongoing trials to expand the target patient pool

Key Upcoming Catalysts

Telitacicept (RC18)

- Results of China NRDL negotiations in 4Q26
- Top line data of global MG Phase III results by Vor in 1H27 and BLA submission in 4Q2027
- Data of OMG China Phase III results in 1H27

Disitamab Vedotin (RC48)

- Results of China NRDL negotiation for 1L UC in 4Q26
- Global Phase III results and BLA filing for 1L UC by Pfizer in 1H27

RC148

- FPI for RC148+chemo in 1L sq-NSCLC global Phase III study in 4Q2026
- Global clinical progress by AbbVie

IND filings for Multiple NMEs in 2027

RemeGen
荣昌生物